Liu J, Hou X, Li L, Bai W, et al. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Gut 2026 Jan 9:gutjnl-2025-336277. doi: 10.1136/gutjnl-2025-336277.
PMID: 41513443